invasive meningococcal disease (serogroups A, C, W-135, Y)
Vaccines · 2018–2018
1decision
1medicine
1carried consumer input
1individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| meningococcal (groups A, C, W-135 and Y) oligosaccharide CRM197 conjugate vaccine Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y in adolescents aged approximately 15 years, with a… | Aug 2018 | Recommended with restriction | 1 individuals Meningitis Centre Australia |
Who spoke
Meningitis Centre Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.